Overview

• Polaris Lawyers has received more than 300 inquiries from individuals reporting neurological injuries linked to high-dose B6 products, prompting a class action investigation against Blackmores.
• The Therapeutic Goods Administration published an interim decision to classify supplements containing over 50mg of vitamin B6 as pharmacist-only medicines, with behind-counter sales set to begin in February 2027 pending final approval.
• The TGA cited evidence of peripheral neuropathy in people taking less than 50mg of supplemental B6 and noted large inter-individual differences in sensitivity to vitamin toxicity.
• A 2022 TGA alert logged 174 reports of nerve-damage conditions associated with B6 toxicity and highlighted concerns over under-reporting and unlabeled vitamin content in multi-ingredient supplements.
• Blackmores asserts that all its B6-containing products meet current TGA requirements and says it will comply fully with any forthcoming regulatory changes.